DURASONE
DEAD

Serial Number

76113585

Owner

EPIGENESIS Pharmaceuticals, Inc.

Attorney

VIVIANA AMZEL

Filing Date

Aug 16, 2000

Add to watchlist:

No watchlists yet
View on USPTO

DURASONE Trademark

Serial Number: 76113585 • Registration: 2611636

DURASONE is a trademark filed by EPIGENESIS Pharmaceuticals, Inc. on August 16, 2000. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

EPIGENESIS Pharmaceuticals, Inc. (26 trademarks)

2055 East Park
Cranbury, NJ 08512

Entity Type: 03

Trademark Details

Filing Date

August 16, 2000

Registration Date

August 27, 2002

Published for Opposition

June 4, 2002

Cancellation Date

May 16, 2009

Goods & Services

Describing and providing medical diagnostic and pharmaceutical preparations with anti-sense oligonucleotides for testing, preventing, and therapeutically treating human and non-human animal respiratory ailments that may be associated with hyper-sensitivity or hyper-responsiveness to adenosine, including bronchoconstriction, difficult breathing; impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in many cases are adenosine receptor associated symptoms; pharmaceutical preparations for the treatment of airway and pulmonary diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating SuperaVentricular Tachycardia (STV), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g., colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, etc, as well as all other metastatic cancers, e.g., cancers which metastasized to the lung(s), breast, liver and prostate

Filing History

CANCELLED SEC. 8 (6-YR)
May 16, 2009 C8..
CASE FILE IN TICRS
Oct 1, 2007 CFIT
REGISTERED-PRINCIPAL REGISTER
Aug 27, 2002 R.PR
PUBLISHED FOR OPPOSITION
Jun 4, 2002 PUBO
NOTICE OF PUBLICATION
May 15, 2002 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 30, 2002 CNSA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 27, 2001 CRFA
NON-FINAL ACTION MAILED
Mar 22, 2001 CNRT
ASSIGNED TO EXAMINER
Mar 14, 2001 DOCK
ASSIGNED TO EXAMINER
Feb 16, 2001 DOCK